MOTS-c
MOTS-c stress experiments
A peptide encoded in mitochondrial DNA travels to the nucleus when cells are under strain. The human story takes a less comfortable turn in dialysis.
Mitochondria and nuclear gene activity
MOTS-c is a 16-amino-acid peptide whose instructions sit within mitochondrial DNA. Mitochondria help turn food into usable energy. A review of MOTS-c, stress and metabolism describes how this small peptide became a subject of research into glucose handling and aging.
In human and mouse cell cultures under metabolic stress, MOTS-c moved into the nucleus and regulated gene activity, including stress-response genes. Its action depended on AMPK, a protein involved in responding to energy shortage. Other laboratory work connects MOTS-c with changes to the folate cycle and the making of material used in DNA.
The traffic between a cell’s energy machinery and its nucleus fascinates me. It gives a physical route to an otherwise rather vague phrase, “metabolic signaling.” These are cell findings. Their fascination survives the absence of a demonstrated human treatment benefit.
Mouse muscle experiments
A study of mice and cell-free systems identified casein kinase 2, or CK2, as a direct MOTS-c target. CK2 activity changed differently in muscle and fat. The investigators found greater glucose uptake into mouse muscle and prevention of muscle atrophy, the loss of muscle tissue.
Another study found that giving MOTS-c to mice improved treadmill performance, grip strength and gait, including in older mice. Exercise also increased the MOTS-c the animals made themselves. That combination is intriguing: a response associated with exertion could also be manipulated experimentally.
I’d be excited to see human treatment research that measures actual physical function. For now, the mouse findings leave human strength, mobility and long-term safety unanswered. Existing amounts used in animals cannot supply a human treatment schedule.
Dialysis cohort
The human study followed 94 people receiving chronic hemodialysis for a median of 26.5 months. Higher circulating MOTS-c was associated with all-cause death or a nonfatal cardiovascular event. Adding the blood measurement modestly improved the investigators’ risk prediction.
Nobody received MOTS-c as treatment. This was a study of a substance already circulating in people with serious kidney disease. It cannot show that MOTS-c caused harm, that more would help, or that giving it to someone else would reproduce the association.
The cheerful version of this story loses me when every increase in an “energy peptide” becomes an improvement. Here the association pointed toward a worse outcome in a particular group. The possible explanations remain open. A stress-related signal can be informative while its treatment implications remain unsettled.
MOTS-c safety
MOTS-c has no FDA approval for human use. There is no approved human formulation, indication or dosing. The cited work contains no completed human efficacy trial demonstrating benefit from administering it, and no validated human half-life, bioavailability or dose-response from which to derive treatment directions.
The research also has limits within its earlier stages. Some mechanistic findings await independent replication; some human biomarker studies are small. Findings involving ancestry and inherited mitochondrial variation suggest that biological responses may differ between populations. The MOTS-c review provides context for the cell and animal literature.
Research material may vary in identity, purity and sterility. MOTS-c is treated as prohibited in elite sport under anti-doping rules. Neither a sporting prohibition nor an attractive mechanism establishes treatment efficacy. I’d leave MOTS-c among the experimental studies, where the unanswered questions remain visible.